[PubMed] [Google Scholar] 58. different criteria in use for determining therapeutic response based on surrogate biomarkers. Fibrates appear to be the most promising new therapy and have beneficially affected surrogate end points and are beginning to show improvement in clinical end points. antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med. 2013;13:245C250. [PubMed] [Google Scholar] 10. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473C476. [PMC free article] [PubMed] [Google Scholar] 11. Kaplan MM. em Novosphingobium aromaticivorans /em : a potential initiator of primary biliary cirrhosis. Am J Gastroenterol. 2004;99:2147C2149. [PubMed] [Google Scholar] 12. Selmi C, Balkwill DL, Invernizzi P, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250C1257. [PubMed] [Google Scholar] 13. Agarwal K, Jones DEJ, Watt FE, et al. Familial primary biliary cirrhosis and autoimmune cholangitis. Dig Liv Dis. 2002;34:50C52. [PubMed] [Google Scholar] 14. Chascsa DM, Lindor KD. Antimitochondrial antibody-negative primary biliary cholangitis: is it really the same disease? Clin Liv Dis. 2018;22:589C601. [PubMed] [Google Scholar] 15. Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525C3531. [PubMed] [Google Scholar] 16. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261C1273. [PubMed] [Google Scholar] 17. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394C419. [PubMed] [Google Scholar] 18. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291C308. [PubMed] [Google Scholar] 19. Doniach D, Walker G. Mitochondrial antibodies (AMA) Gut. 1974;15:664C668. [PMC free article] [PubMed] [Google Scholar] 20. Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol (Australia) 2006;21:1448C1454. [PubMed] [Google Scholar] 21. Hu S, Zhao F, Wang Q, et al. Niraparib tosylate The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014;52:1533C1542. [PubMed] [Google Scholar] 22. Juliusson G, Imam M, Bj?rnsson ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745C752. [PubMed] [Google Scholar] 23. Kadokawa Y, Omagari K, Ohba K, et al. Does the diagnosis of primary biliary cirrhosis of autoimmune cholangitis depend on the ‘phase’ of the disease? Liv Int. 2005;25:317C324. [PubMed] [Google Scholar] 24. Munoz LE, Thomas HC, Scheuer PJ, et al. Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut. 1981;22:136C140. [PMC free article] [PubMed] [Google Scholar] 25. Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta. 2012;413:1211C1216. [PubMed] [Google Scholar] 26. Ozaslan E, Efe C, Gokbulut ON. The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol. 2016;40:553C561. [PubMed] [Google Scholar] 27. Vleggaar FP, Van Buuren HR. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis. Hepatogastroenterology. 2004;51:937C940. [PubMed] [Google Scholar] 28. Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60:236C248. [PubMed] [Google Scholar] 29. ter Borg PC, Schalm SW, Hansen BE, et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044C2050. [PubMed] [Google Scholar] 30. Hashimoto E, Taniai M, Yatsuji S, et al. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol Res. 2007;37:S455CS461. [PubMed] [Google Scholar] 31. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) Virchows Arch A Pathol Anat Histol. 1978;379:103C112. [PubMed] [Google Scholar] 32. Cholankeril G, Gonzalez HC, Satapathy SK, et al. Increased waitlist mortality and lower rate for liver transplantation in Hispanic patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2018;16(965C973):e2. [PMC free article] [PubMed] [Google Scholar] 33. Galoosian A, Hanlon C, Tana M, et al. Race/ethnicity and insurance-specific disparities in in-hospital mortality among adults with primary biliary cholangitis: analysis of 2007C2014 national inpatient sample. Dig Dis Sci. 2019 doi:?10.1007/s10620-019-05809. [PubMed] [CrossRef] [Google Scholar] 34. Lu M, Li J, Haller IV, et al. Factors associated with prevalence and treatment of primary.Recent advances in the development of farnesoid X receptor agonists. that the disease is heterogeneous, hard end points take years to develop, and there are different criteria in use for determining therapeutic response based on surrogate biomarkers. Fibrates appear to be the most promising new therapy and have beneficially affected surrogate end points and are beginning to show improvement in clinical end points. antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med. 2013;13:245C250. [PubMed] [Google Scholar] 10. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473C476. [PMC free article] [PubMed] [Google Scholar] 11. Kaplan MM. em Novosphingobium aromaticivorans /em : a potential initiator of primary biliary cirrhosis. Am J Gastroenterol. 2004;99:2147C2149. [PubMed] [Google Scholar] 12. Selmi C, Balkwill DL, Invernizzi P, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250C1257. [PubMed] [Google Scholar] 13. Agarwal K, Jones DEJ, Watt FE, et al. Familial primary biliary cirrhosis and autoimmune cholangitis. Dig Liv Dis. 2002;34:50C52. [PubMed] [Google Scholar] 14. Chascsa DM, Lindor KD. Antimitochondrial antibody-negative primary biliary cholangitis: is it really the same disease? Clin Liv Dis. 2018;22:589C601. [PubMed] [Google Scholar] 15. Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525C3531. [PubMed] [Google Scholar] 16. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261C1273. [PubMed] [Google Scholar] 17. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394C419. [PubMed] [Google Scholar] 18. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291C308. [PubMed] [Google Scholar] 19. Doniach D, Walker G. Mitochondrial antibodies (AMA) Gut. 1974;15:664C668. [PMC free article] [PubMed] [Google Scholar] 20. Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol (Australia) 2006;21:1448C1454. [PubMed] [Google Scholar] 21. Hu S, Zhao F, Wang Q, et al. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014;52:1533C1542. [PubMed] [Google Scholar] 22. Juliusson G, Imam M, Bj?rnsson ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745C752. [PubMed] [Google Scholar] 23. Kadokawa Y, Omagari K, Ohba K, et al. Does the diagnosis of primary biliary cirrhosis of autoimmune cholangitis depend on the ‘phase’ of the disease? Liv Int. 2005;25:317C324. [PubMed] [Google Scholar] 24. Munoz LE, Thomas HC, Scheuer PJ, et al. Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut. 1981;22:136C140. [PMC GDNF free article] [PubMed] [Google Scholar] 25. Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta. 2012;413:1211C1216. [PubMed] [Google Niraparib tosylate Scholar] 26. Ozaslan E, Efe C, Gokbulut ON. The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clin Res Hepatol Gastroenterol. 2016;40:553C561. [PubMed] [Google Scholar] 27. Vleggaar FP, Van Buuren HR. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis. Hepatogastroenterology. 2004;51:937C940. [PubMed] [Google Scholar] 28. Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60:236C248. [PubMed] [Google Scholar] 29. ter Borg PC, Schalm SW, Hansen BE, et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044C2050. [PubMed] [Google Scholar] 30. Hashimoto E, Taniai M, Yatsuji S, et al. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol.[PubMed] [Google Scholar] 55. response based on surrogate biomarkers. Fibrates seem to be one of the most appealing new therapy and also have beneficially affected surrogate end factors and are starting to present improvement in scientific end factors. antibody in Chinese language patients with principal biliary cirrhosis. Clin Exp Med. 2013;13:245C250. [PubMed] [Google Scholar] 10. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver organ illnesses. Clin Exp Immunol. 2003;132:473C476. [PMC free of charge content] [PubMed] [Google Scholar] 11. Kaplan MM. em Novosphingobium aromaticivorans /em : a potential initiator of principal biliary cirrhosis. Am J Gastroenterol. 2004;99:2147C2149. [PubMed] [Google Scholar] 12. Selmi C, Balkwill DL, Invernizzi P, et al. Sufferers with principal biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250C1257. [PubMed] [Google Scholar] 13. Agarwal K, Jones DEJ, Watt FE, et al. Familial principal biliary cirrhosis and autoimmune cholangitis. Drill down Liv Dis. 2002;34:50C52. [PubMed] [Google Scholar] 14. Chascsa DM, Lindor KD. Antimitochondrial antibody-negative principal biliary cholangitis: could it be actually the same disease? Clin Liv Dis. 2018;22:589C601. [PubMed] [Google Scholar] 15. Gershwin Me personally, Mackay IR, Sturgess A, et al. Id and specificity of the cDNA encoding the 70 kd mitochondrial antigen regarded in principal biliary cirrhosis. J Immunol. 1987;138:3525C3531. [PubMed] [Google Scholar] 16. Kaplan MM, Gershwin Me personally. Principal biliary cirrhosis. N Engl J Med. 2005;353:1261C1273. [PubMed] [Google Scholar] 17. Lindor KD, Bowlus CL, Boyer J, et al. Principal biliary cholangitis: 2018 practice assistance in the American Association for the analysis of Liver Illnesses. Hepatology. 2019;69:394C419. [PubMed] [Google Scholar] 18. Lindor KD, Gershwin Me personally, Poupon R, et al. Principal biliary cirrhosis. Hepatology. 2009;50:291C308. [PubMed] [Google Scholar] 19. Doniach D, Walker G. Mitochondrial antibodies (AMA) Gut. 1974;15:664C668. [PMC free of charge content] [PubMed] [Google Scholar] 20. Nezu S, Tanaka A, Yasui H, et al. Existence of antimitochondrial autoantibodies in sufferers with autoimmune hepatitis. J Gastroenterol Hepatol (Australia) 2006;21:1448C1454. [PubMed] [Google Scholar] 21. Hu S, Zhao F, Wang Q, et al. The precision from the anti-mitochondrial antibody as well as the M2 subtype check for medical diagnosis of principal biliary cirrhosis: a meta-analysis. Clin Chem Laboratory Med. 2014;52:1533C1542. [PubMed] [Google Scholar] 22. Juliusson G, Imam M, Bj?rnsson Ha sido, et al. Long-term final results in antimitochondrial antibody detrimental principal biliary cirrhosis. Scand J Gastroenterol. 2016;51:745C752. [PubMed] [Google Scholar] 23. Kadokawa Y, Omagari K, Ohba K, et al. Will the medical diagnosis of principal biliary cirrhosis of autoimmune cholangitis depend over the ‘stage’ of the condition? Liv Int. 2005;25:317C324. [PubMed] [Google Scholar] 24. Munoz LE, Thomas HC, Scheuer PJ, et al. Is normally mitochondrial antibody diagnostic of principal biliary cirrhosis? Gut. 1981;22:136C140. [PMC free of charge content] [PubMed] [Google Scholar] 25. Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and scientific tool of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in sufferers with principal biliary cirrhosis. Clin Chim Acta. 2012;413:1211C1216. [PubMed] [Google Scholar] 26. Ozaslan E, Efe C, Gokbulut ON. The medical diagnosis of antimitochondrial antibody-negative principal biliary cholangitis. Clin Res Hepatol Gastroenterol. 2016;40:553C561. [PubMed] [Google Scholar] 27. Vleggaar FP, Truck Buuren HR. No prognostic need for antimitochondrial antibody profile examining in principal biliary cirrhosis. Hepatogastroenterology. 2004;51:937C940. [PubMed] [Google Scholar] 28. Portmann B, Zen Y. Inflammatory disease from the bile ducts-cholangiopathies: Niraparib tosylate liver organ biopsy problem and clinicopathological relationship. Histopathology. 2012;60:236C248. [PubMed] [Google Scholar] 29. ter Borg Computer, Schalm SW, Hansen End up being, et al. Prognosis of ursodeoxycholic acid-treated sufferers with principal biliary cirrhosis. Outcomes of the 10-yr cohort research involving 297 sufferers. Am J Gastroenterol. 2006;101:2044C2050. [PubMed] [Google Scholar] 30. Hashimoto E, Taniai M, Yatsuji S, et al. Long-term scientific final result of living-donor liver organ transplantation for principal biliary cirrhosis. Hepatol Res. 2007;37:S455CS461. [PubMed] [Google Scholar] 31. Ludwig J, Dickson ER, McDonald GS. Staging of persistent nonsuppurative damaging cholangitis (symptoms of principal biliary cirrhosis) Virchows Arch A Pathol Anat Histol. 1978;379:103C112. [PubMed] [Google Scholar] 32. Cholankeril G, Gonzalez HC, Satapathy SK, et al. Elevated waitlist mortality and lower price for liver organ transplantation in.Ten-year survival in ursodeoxycholic acid-treated sufferers with principal biliary cirrhosis. 2013;13:245C250. [PubMed] [Google Scholar] 10. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver organ illnesses. Clin Exp Immunol. 2003;132:473C476. [PMC free of charge content] [PubMed] [Google Scholar] 11. Kaplan MM. em Novosphingobium aromaticivorans /em : a potential initiator of principal biliary cirrhosis. Am J Gastroenterol. 2004;99:2147C2149. [PubMed] [Google Scholar] 12. Selmi C, Balkwill DL, Invernizzi P, et al. Sufferers with principal biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003;38:1250C1257. [PubMed] [Google Scholar] 13. Agarwal K, Jones DEJ, Watt FE, et al. Familial principal biliary cirrhosis and autoimmune cholangitis. Drill down Liv Dis. 2002;34:50C52. [PubMed] [Google Scholar] 14. Chascsa DM, Lindor KD. Antimitochondrial antibody-negative principal biliary cholangitis: could it be actually the same disease? Clin Liv Dis. 2018;22:589C601. [PubMed] [Google Scholar] 15. Gershwin Me personally, Mackay IR, Sturgess A, et al. Id and specificity of the cDNA encoding the 70 kd mitochondrial antigen regarded in principal biliary cirrhosis. J Immunol. 1987;138:3525C3531. [PubMed] [Google Scholar] 16. Kaplan MM, Gershwin Me personally. Principal biliary cirrhosis. N Engl J Med. 2005;353:1261C1273. [PubMed] [Google Scholar] 17. Lindor KD, Bowlus CL, Boyer J, et al. Principal biliary cholangitis: 2018 practice assistance in the American Association for the analysis of Liver Illnesses. Hepatology. 2019;69:394C419. [PubMed] [Google Scholar] 18. Lindor KD, Gershwin Me personally, Poupon R, et al. Principal biliary cirrhosis. Hepatology. 2009;50:291C308. [PubMed] [Google Scholar] 19. Doniach D, Walker G. Mitochondrial antibodies (AMA) Gut. 1974;15:664C668. [PMC free of charge content] [PubMed] [Google Scholar] 20. Nezu S, Tanaka A, Yasui H, et al. Existence of antimitochondrial autoantibodies in sufferers with autoimmune hepatitis. J Gastroenterol Hepatol (Australia) 2006;21:1448C1454. [PubMed] [Google Scholar] 21. Hu S, Zhao F, Wang Q, et al. The precision from the anti-mitochondrial antibody as well as the M2 subtype check for medical diagnosis of principal biliary cirrhosis: a meta-analysis. Clin Chem Laboratory Med. 2014;52:1533C1542. [PubMed] [Google Scholar] 22. Juliusson G, Imam M, Bj?rnsson Ha sido, et al. Long-term final results in antimitochondrial antibody detrimental principal biliary cirrhosis. Scand J Gastroenterol. 2016;51:745C752. [PubMed] [Google Scholar] 23. Kadokawa Y, Omagari K, Ohba K, et al. Will the medical diagnosis of principal biliary cirrhosis of autoimmune cholangitis depend over the ‘stage’ of the condition? Liv Int. 2005;25:317C324. [PubMed] [Google Scholar] 24. Munoz LE, Thomas HC, Scheuer PJ, et al. Is normally mitochondrial antibody diagnostic of principal biliary cirrhosis? Gut. 1981;22:136C140. [PMC free of charge article] [PubMed] [Google Scholar] 25. Mytilinaiou MG, Meyer W, Scheper T, et al. Diagnostic and clinical power of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with main biliary cirrhosis. Clin Chim Acta. 2012;413:1211C1216. [PubMed] [Google Scholar] 26. Ozaslan E, Efe C, Gokbulut ON. The diagnosis of antimitochondrial antibody-negative main biliary cholangitis. Clin Res Hepatol Gastroenterol. 2016;40:553C561. [PubMed] [Google Scholar] 27. Vleggaar FP, Van Buuren HR. No prognostic significance of antimitochondrial antibody profile screening in main biliary cirrhosis. Hepatogastroenterology. 2004;51:937C940. [PubMed] [Google Scholar] 28. Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60:236C248. [PubMed] [Google Scholar] 29. ter Borg PC, Schalm SW, Hansen BE, et al. Prognosis of ursodeoxycholic acid-treated patients with main biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044C2050. [PubMed] [Google Scholar] 30. Hashimoto E, Taniai M, Yatsuji S, et al. Long-term clinical end result of living-donor liver transplantation for main biliary cirrhosis. Hepatol Res. 2007;37:S455CS461. [PubMed] [Google Scholar] 31. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of main biliary cirrhosis) Virchows Arch A Pathol Anat Histol. 1978;379:103C112. [PubMed] [Google Scholar] 32. Cholankeril G, Gonzalez HC, Satapathy SK, et al. Increased waitlist mortality and lower rate for liver transplantation in Hispanic patients with main biliary cholangitis. Clin Gastroenterol Hepatol. 2018;16(965C973):e2. [PMC free article] [PubMed] [Google Scholar] 33. Galoosian A, Hanlon C, Tana M, et al. Race/ethnicity and insurance-specific disparities in in-hospital mortality.